FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2062169556> ?p ?o ?g. }

• W2062169556 endingPage "754" @default.
• W2062169556 startingPage "746" @default.
• W2062169556 abstract "A HIV-1 tier system has been developed to categorize the various subtype viruses based on their sensitivity to vaccine-induced neutralizing antibodies (NAbs): tier 1 with greatest sensitivity, tier 2 being moderately sensitive, and tier 3 being the least sensitive to NAbs (Mascola et al., J Virol 2005; 79:10103–7). Here, we define an FIV tier system using two related FIV dual-subtype (A + D) vaccines: the commercially available inactivated infected-cell vaccine (Fel-O-Vax® FIV) and its prototype vaccine solely composed of inactivated whole viruses. Both vaccines afforded combined protection rates of 100% against subtype-A tier-1 FIVPet, 89% against subtype-B tier-3 FIVFC1, 61% against recombinant subtype-A/B tier-2 FIVBang, 62% against recombinant subtype-F′/C tier-3 FIVNZ1, and 40% against subtype-A tier-2 FIVUK8 in short-duration (37–41 weeks) studies. In long-duration (76–80 weeks) studies, the commercial vaccine afforded a combined protection rate of at least 46% against the tier-2 and tier-3 viruses. Notably, protection rates observed here are far better than recently reported HIV-1 vaccine trials (Sanou et al., The Open AIDS J 2012; 6:246–60). Prototype vaccine protection against two tier-3 and one tier-2 viruses was more effective than commercial vaccine. Such protection did not correlate with the presence of vaccine-induced NAbs to challenge viruses. This is the first large-scale (228 laboratory cats) study characterizing short- and long-duration efficacies of dual-subtype FIV vaccines against heterologous subtype and recombinant viruses, as well as FIV tiers based on in vitro NAb analysis and in vivo passive-transfer studies. These studies demonstrate that not all vaccine protection is mediated by vaccine-induced NAbs." @default.
• W2062169556 created "2016-06-24" @default.
• W2062169556 creator A5020158904 @default.
• W2062169556 creator A5068881321 @default.
• W2062169556 creator A5071448494 @default.
• W2062169556 creator A5086247539 @default.
• W2062169556 creator A5029156689 @default.
• W2062169556 creator A5046276541 @default.
• W2062169556 date "2014-02-01" @default.
• W2062169556 modified "2023-10-14" @default.
• W2062169556 title "Feline immunodeficiency virus (FIV) vaccine efficacy and FIV neutralizing antibodies" @default.
• W2062169556 cites W1527195428 @default.
• W2062169556 cites W1778074134 @default.
• W2062169556 cites W1794361841 @default.
• W2062169556 cites W1964077677 @default.
• W2062169556 cites W1978407444 @default.
• W2062169556 cites W1979399702 @default.
• W2062169556 cites W1992071350 @default.
• W2062169556 cites W1992195576 @default.
• W2062169556 cites W1993846907 @default.
• W2062169556 cites W2003721378 @default.
• W2062169556 cites W2017172686 @default.
• W2062169556 cites W2018948451 @default.
• W2062169556 cites W2020100193 @default.
• W2062169556 cites W2020461877 @default.
• W2062169556 cites W2021900417 @default.
• W2062169556 cites W2026678964 @default.
• W2062169556 cites W2032086068 @default.
• W2062169556 cites W2033049092 @default.
• W2062169556 cites W2037355038 @default.
• W2062169556 cites W2050317773 @default.
• W2062169556 cites W2051281891 @default.
• W2062169556 cites W2064304633 @default.
• W2062169556 cites W2064703363 @default.
• W2062169556 cites W2081539383 @default.
• W2062169556 cites W2082262486 @default.
• W2062169556 cites W2094385855 @default.
• W2062169556 cites W2104691524 @default.
• W2062169556 cites W2117027952 @default.
• W2062169556 cites W2123266716 @default.
• W2062169556 cites W2124470728 @default.
• W2062169556 cites W2125235576 @default.
• W2062169556 cites W2126726007 @default.
• W2062169556 cites W2134756173 @default.
• W2062169556 cites W2144294011 @default.
• W2062169556 cites W2152048324 @default.
• W2062169556 cites W2153670011 @default.
• W2062169556 cites W2155134568 @default.
• W2062169556 cites W2169352260 @default.
• W2062169556 cites W2173058911 @default.
• W2062169556 cites W2240372320 @default.
• W2062169556 cites W2470298560 @default.
• W2062169556 cites W4239768034 @default.
• W2062169556 cites W83189670 @default.
• W2062169556 doi "https://doi.org/10.1016/j.vaccine.2013.05.024" @default.
• W2062169556 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4304674" @default.
• W2062169556 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23800540" @default.
• W2062169556 hasPublicationYear "2014" @default.
• W2062169556 type Work @default.
• W2062169556 sameAs 2062169556 @default.
• W2062169556 citedByCount "18" @default.
• W2062169556 countsByYear W20621695562014 @default.
• W2062169556 countsByYear W20621695562015 @default.
• W2062169556 countsByYear W20621695562016 @default.
• W2062169556 countsByYear W20621695562017 @default.
• W2062169556 countsByYear W20621695562018 @default.
• W2062169556 countsByYear W20621695562019 @default.
• W2062169556 countsByYear W20621695562020 @default.
• W2062169556 countsByYear W20621695562021 @default.
• W2062169556 countsByYear W20621695562022 @default.
• W2062169556 crossrefType "journal-article" @default.
• W2062169556 hasAuthorship W2062169556A5020158904 @default.
• W2062169556 hasAuthorship W2062169556A5029156689 @default.
• W2062169556 hasAuthorship W2062169556A5046276541 @default.
• W2062169556 hasAuthorship W2062169556A5068881321 @default.
• W2062169556 hasAuthorship W2062169556A5071448494 @default.
• W2062169556 hasAuthorship W2062169556A5086247539 @default.
• W2062169556 hasBestOaLocation W20621695562 @default.
• W2062169556 hasConcept C104317684 @default.
• W2062169556 hasConcept C159047783 @default.
• W2062169556 hasConcept C159654299 @default.
• W2062169556 hasConcept C203014093 @default.
• W2062169556 hasConcept C22070199 @default.
• W2062169556 hasConcept C2522874641 @default.
• W2062169556 hasConcept C2777841672 @default.
• W2062169556 hasConcept C2778190748 @default.
• W2062169556 hasConcept C2779261636 @default.
• W2062169556 hasConcept C2779690655 @default.
• W2062169556 hasConcept C2780115692 @default.
• W2062169556 hasConcept C2780195530 @default.
• W2062169556 hasConcept C2780727368 @default.
• W2062169556 hasConcept C55493867 @default.
• W2062169556 hasConcept C71924100 @default.
• W2062169556 hasConcept C86803240 @default.
• W2062169556 hasConceptScore W2062169556C104317684 @default.
• W2062169556 hasConceptScore W2062169556C159047783 @default.
• W2062169556 hasConceptScore W2062169556C159654299 @default.
• W2062169556 hasConceptScore W2062169556C203014093 @default.

• next